sur Biotest AG (isin : DE0005227201)
Biotest Sees 35% Sales Spike in First Half of 2024
Biotest AG reported a significant increase in sales for the first half of 2024, reaching €372 million, a 35.1% rise from the previous year's €275.3 million. The company achieved an EBIT of €78.4 million, driven by revenue from technology disclosure and development services for Grifols, S.A.
The new intravenous immunoglobulin, Yimmugo®, contributed notably with revenues increasing from €16.0 million to €25.6 million. Additionally, Biotest's Dreieich facility received FDA certification in June 2024, alongside FDA approval for Yimmugo® for treating primary immunodeficiencies.
For the second half of 2024, Biotest foresees continued revenue growth in the upper single-digit percentage range. This projection includes sustained earnings from technology disclosures and development services, with an estimated EBIT between €80 million and €100 million, and positive cash flow from operations.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biotest AG